+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bipolar Disorder Disease Coverage

  • ID: 5206542
  • Report
  • October 2020
  • Region: Global
  • 75 pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now
Latest Key Takeaways

The publisher estimates that in 2018, there were 46.2 million prevalent cases of bipolar disorder (BD) worldwide, and forecasts that number to increase to 50.4 million prevalent cases by 2027.

The BD market is highly genericized, consisting of antipsychotics, anticonvulsants, and mood stabilizers, such as lithium. The atypical antipsychotic market is the most dominant of the drug classes indicated for BD, and the oral atypical antipsychotic market is highly competitive with many generic alternatives available. The atypical long-acting injectable (LAI) antipsychotic market currently faces little competition and is therefore one of the key areas to target for growth, along with the development of drugs focusing on other underserved BD patient segments.

Some of the most impactful recent events that have occurred in the BD space include the positive review from the FDA Advisory Committee meeting for Alkermes’s ALKS 3831 ahead of its November PDUFA date, though panel members underscored the necessity for wide education of the associated opioid antagonism risks. Additionally, Intra-Cellular Therapies’ Caplyta and BioXcel’s BXCL501 both provided positive topline pivotal trial results in BD depression and acutely agitated BD patients, respectively.

As physicians and patients become more accustomed to the dosing regimens of LAIs and their associated benefits, their uptake will increase. Pharmaceutical treatment compliance is a major issue in BD, and physicians will encourage switching to LAI formulations to reduce relapses. There are only two key brands in the BD LAI atypical antipsychotic market: Risperdal Consta - the first of its kind approved for BD, requiring biweekly dosing; and Abilify Maintena, which only requires a once-monthly administration.

Seroquel/Seroquel XR has a robust clinical profile in BD, due to its strong efficacy as both a monotherapy and adjuvant in the treatment BD mania, a BD maintenance treatment, and in BD depression. The drug is one of few therapies specifically approved for BD depression. As a monotherapy in trials, treatment in both type I and II BD patients elicited some of the greatest improvements over placebo that have been witnessed in controlled BD studies. As an atypical antipsychotic, Seroquel/Seroquel XR has modest safety/tolerability profiles at best. Nevertheless, both formulations are genericized, and the market share of this brand in BD has been cannibalized and will continue to plummet.

Abilify Maintena is one of the few approved LAI antipsychotics available for BD, and its increasing uptake means it is likely to dominate the bipolar LAI market. The drug boasts one of the highest rates of relapse reduction over placebo in clinical trials, granting it a position towards the top of the BD maintenance treatment algorithm. Abilify Maintena can be administered once-monthly, surpassing that of Risperdal Consta’s biweekly dosing regimen, and this less frequent dosing provides further aid to the mitigation of compliance issues so often seen with antipsychotics. With the associated benefits of LAIs, and as both physicians and patients become more accustomed to the dosing regimens, the LAI market should see sizable growth.

Pipeline drug developers are targeting unmet needs in BD for which there are currently limited options available, and consequently, these pipeline drugs will act to drive growth in the market, if successfully approved. Intra-Cellular Therapies has gathered encouraging data from trials investigating the adjunctive and monotherapy use of Caplyta in type I and II BD depression patients. Only Latuda is approved as an adjunctive/monotherapy treatment for BD depression, and also has demonstrable efficacy in type II BD depressed patients, specifically. Intra-Cellular would therefore be offering another much-needed option in this subpopulation, and moreover, Caplyta displayed minimal motor adverse events in pivotal trials, compared to the higher rates witnessed in Latuda’s regulatory studies.

Alkermes’s ALKS 3831, a distinct formulation of olanzapine and the novel opioid receptor antagonist samidorphan, is an antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain, a firmly established side-effect of most antipsychotics. In trials, the drug has demonstrated similar efficacy to olanzapine in schizophrenia patients and statistically significant reduced weight gain. After the recent positive FDA Advisory Committee meeting, the regulatory body is expected to deliver the ALKS 3831 approval decision by the November 2020 PDUFA date.

In addition to the FDA’s pending decision on Alkermes’s ALKS 3831 for the treatment of BD and schizophrenia in November, a further key upcoming event in the BD space is Intra-Cellular Therapies’ projected sNDA submission for Caplyta in the treatment of BD depression, to include BD type II specifically.
Note: Product cover images may vary from those shown
OVERVIEW
  • Latest key takeaways
DISEASE BACKGROUND
  • Definition
  • Patient segmentation
TREATMENT
  • Drug therapy is used in the vast majority of bipolar disorder patients
  • Therapy can be integrated with non-pharmacological interventions to improve patient outcomes
  • The goal of treatment is to bring patients to a state of recovery and minimize relapses
  • Bipolar disorder treatment guideline recommendations by drug class
  • Acute mania
  • Acute depression
  • Maintenance therapy
EPIDEMIOLOGY
  • Prevalence methodology
MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS
  • Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan
  • Approvals To Look Out For In Q4
  • Alkermes’ Antipsychotic Combo Faces US FDA Questions On Metabolic Effects, Opioid-Related Safety
  • Alkermes Tries Again With Samidorphan, This Time With Olanzapine
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • AstraZeneca Sells Mature Brands For $421m+
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
  • DRUG ASSESSMENT MODEL
  • Marketed drugs
  • Pipeline drugs
MARKET DYNAMICS

FUTURE TRENDS
  • The LAI atypical antipsychotic market will see increasing growth and little competition
  • The oral atypical antipsychotic market will see further widespread genericization
  • Potential market entrants will be directed towards underserved patient segments and improved tolerability
CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION
  • ALKS 3831 for Bipolar Disorder (October 9, 2020)
  • ALKS 3831 for Bipolar Disorder (October 7, 2020)
  • Caplyta for Bipolar Disorder (September 9, 2020)
  • BXCL501 for Bipolar Disorder (July 20, 2020)
  • SEP-4199 for Bipolar Disorder (July 6, 2020)
  • SAGE-217 for Bipolar Disorder (July 24, 2019)
  • Caplyta for Bipolar Disorder (July 8, 2019)
  • Multiple Drugs for Bipolar Disorder (June 25, 2019)
KEY UPCOMING EVENTS

UNMET NEEDS
  • BD depression
  • Delay of correct diagnosis
  • Cognitive impairment
BIBLIOGRAPHY
  • Prescription information
APPENDIX

List of Figures
  • Figure 1: DSM-5 diagnostic criteria for mood episodes based on symptoms
  • Figure 2: DSM-5 diagnostic criteria for bipolar disorder subtypes
  • Figure 3: Psychological interventions for bipolar disorder
  • Figure 4: Guidelines for bipolar disorder treatment
  • Figure 5: Drug classes recommended in bipolar disorder treatment guidelines, by disease phase and line of therapy
  • Figure 6: Guideline recommendations for acute mania, by line of treatment
  • Figure 7: Guideline recommendations for acute depression, by line of treatment
  • Figure 8: Guideline recommendations for maintenance therapy, by line of treatment
  • Figure 9: Trends in prevalent cases of bipolar disorder, 2018-27
  • Figure 10: Overview of pipeline drugs for bipolar disorder in the US
  • Figure 11: Pipeline drugs for bipolar disorder, by company
  • Figure 12: Pipeline drugs for bipolar disorder, by drug type
  • Figure 13: Pipeline drugs for bipolar disorder, by classification
  • Figure 14: Probability of success in the bipolar disorder pipeline
  • Figure 15: Clinical trials in bipolar disorder
  • Figure 16: Top 10 drugs for clinical trials in bipolar disorder
  • Figure 17: Top 10 companies for clinical trials in bipolar disorder
  • Figure 18: Trial locations in bipolar disorder
  • Figure 19: Bipolar disorder trials status
  • Figure 20: Bipolar disorder trials sponsors, by phase
  • Figure 21: Datamonitor Healthcare’s drug assessment summary for bipolar disorder
  • Figure 22: Market dynamics in bipolar disorder
  • Figure 23: Future trends in bipolar disorder
  • Figure 24: Caplyta for Bipolar Disorder (September 9, 2020): Phase III - Study 402 (Adjunctive)
  • Figure 25: BXCL501 for Bipolar Disorder (July 20, 2020): Phase III - SERENITY II
  • Figure 26: SEP-4199 for Bipolar Disorder (July 6, 2020): Phase II - SEP380-201
  • Figure 27: Caplyta for Bipolar Disorder (July 8, 2019): Phase III - Study 401 (Monotherapy), Phase III - Study 404 (Monotherapy)
  • Figure 28: Key upcoming events in bipolar disorder
List of Tables
  • Table 1: Prevalent cases of bipolar disorder, 2018-27
  • Table 2: Marketed drugs for bipolar disorder
  • Table 3: Pipeline drugs for bipolar disorder in the US
  • Table 4: Historical global sales, by drug ($m), 2015-19
  • Table 5: Forecasted global sales, by drug ($m), 2020-24
  • Table 6: ALKS 3831 for Bipolar Disorder (October 9, 2020)
  • Table 7: ALKS 3831 for Bipolar Disorder (October 7, 2020)
  • Table 8: Caplyta for Bipolar Disorder (September 9, 2020)
  • Table 9: BXCL501 for Bipolar Disorder (July 20, 2020)
  • Table 10: SEP-4199 for Bipolar Disorder (July 6, 2020)
  • Table 11: SAGE-217 for Bipolar Disorder (July 24, 2019)
  • Table 12: Caplyta for Bipolar Disorder (July 8, 2019)
  • Table 13: Multiple Drugs for Bipolar Disorder (June 25, 2019)
Note: Product cover images may vary from those shown
Adroll
adroll